# Study of XL820 Given Orally Daily to Subjects With Solid Tumors

> **NCT00350831** · PHASE1 · COMPLETED · sponsor: **Exelixis** · enrollment: 30 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** XL820

## Key facts

- **NCT ID:** NCT00350831
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350831, "Study of XL820 Given Orally Daily to Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00350831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*